Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: A retrospective study using the national multiple sclerosis registry in Kuwait

Background: Fingolimod is an oral sphingosine-1-phosphate-receptor modulator, which has demonstrated efficacy in clinical trials and has recently been approved for multiple sclerosis (MS) treatment in Kuwait. Post-marketing studies are important to demonstrate real-life efficacy and safety. Objective: The objective of this study was to examine the efficacy and safety of fingolimod treatment in a clinical setting.